Shares of Indivior Plummet on Suboxone Patent Ruling

   By Carlo Martuscelli 
 

Shares of Indivior PLC (INDV.LN) plummeted on Tuesday after a U.S. court overturned an injunction against Dr. Reddy's Laboratories Ltd. (500124.BY) preventing the sale of a generic version of Indivior's Suboxone opioid-addiction treatment.

The drugmaker said despite the result it will continue to pursue patent-infringement cases against Dr. Reddy's to protect its Suboxone patent portfolio.

"The company is in the process of interpreting the ruling in its entirety and will issue a statement on its implications once this review has been completed," Indivior said.

In July, the FTSE 250-listed pharmaceutical company was granted an injunction preventing Dr. Reddy's from selling its own generic version of the opioid treatment in the U.S. on the grounds of copy-right infringement. This was subsequently appealed by the Indian company.

Shares of Indivior at 1540 GMT were down 76.85 pence, or 38%, 126.80 pence.

Write to Carlo Martuscelli at [e-mail]

(END) Dow Jones Newswires

November 20, 2018 11:05 ET (16:05 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.